While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...
Kanye Wests online tøjbutik er blevet lukket efter at have vist T-shirts med et hagekors. Det skriver Sky News. Ifølge mediet ...
Berlingske er bekendt med identiteten på Maria Sommer Hjort Kronholms ekskæreste, der blev dømt ét års fængsel for grov vold, ...
Der er fundet tegn på, at masseskyderiet i Örebro i Sverige i sidste uge var planlagt. Det siger vicepolitichef i Bergslagen, ...
Hun har 20 års erfaring fra forskning på Novo Nordisk og Novozymes og har siden 2018 med sin ... I blå nederdel, orange T-shirt og et par mønstrede, ankelhøje sneakers i samme farve. Og parat er ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...
The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...
With sales of Novo Nordisk’s obesity blockbuster Wegovy more than doubling in 2024’s fourth quarter, the Danish drugmaker feels confident that it can maintain its edge over chief rival Eli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback